Greater level of parathyroid hormone (PTH) than healthy subject is required to maintain appropriate bone turnover in dialysis patients. The skeletal resistance to PTH is the most important genesis of this phenomenon and the mechanism has been elucidated by the recent molecular biological techniques. Insufficient level of PTH induces not only adynamic bone disease but also cardiovascular diseases by ectopic calcification in soft tissues. Cardiovascular calcification is an important risk factor for the prognosis of dialysis patients, so the development of new therapeutic tools, that can adequately control PTH levels without hypercalcemia and hyperphosphatemia, are expected.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Jan 2004|
ASJC Scopus subject areas